AirDuo Shortage Update: What Patients Need to Know in 2026

If you've been searching for AirDuo RespiClick and coming up empty, you're not alone — and there's a specific reason for it. This isn't a traditional drug shortage caused by manufacturing problems or supply chain disruptions. AirDuo RespiClick was deliberately discontinued by its manufacturer. Here's everything you need to know about what happened and what to do next.

What Happened to AirDuo RespiClick?

On July 9, 2025, Teva Respiratory discontinued distribution of AirDuo RespiClick (fluticasone propionate and salmeterol inhalation powder) in the United States. Teva stopped selling the brand product to wholesalers as of that date, though some channel inventory remained available at pharmacies for a period after.

This was not an FDA recall, not a safety concern, and not the result of a manufacturing problem. It was a voluntary business decision by Teva to exit the branded AirDuo product line, following the earlier discontinuation of the AirDuo Digihaler (the smart inhaler version) in June 2024.

Is There a Current AirDuo Shortage?

As of 2026, the situation is best described as a discontinuation rather than a traditional shortage. The brand-name AirDuo RespiClick is no longer being manufactured or distributed. Any residual stock in pharmacy channels has been depleted.

However, the American Society of Health-System Pharmacists (ASHP) has tracked fluticasone/salmeterol inhalation powder availability, noting that Teva Respiratory has all presentations available through the authorized generic. This means the active medication is still accessible — just under a different product name.

What Is Still Available in 2026?

Patients who relied on AirDuo RespiClick have several options in 2026:

• Authorized Generic (Teva): Fluticasone Propionate and Salmeterol Inhalation Powder (MDPI) — same drug, same device, same three strengths (55/14, 113/14, 232/14 mcg). This is the most direct replacement.
• Advair Diskus / Advair HFA: Same active ingredients (fluticasone/salmeterol), different inhaler device. Available in brand and generic (Wixela Inhub) versions.
• Symbicort (generic available): Budesonide/formoterol — different ICS/LABA combination, widely stocked.
• Breo Ellipta: Once-daily fluticasone furoate/vilanterol. Good option for patients seeking simplified dosing.

How Does This Affect Your Insurance Coverage?

The authorized generic of AirDuo RespiClick is covered by most Medicare Part D and commercial insurance plans. In many cases, plans already prefer or require generic versions of medications, so your copay for the generic may actually be lower than what you were paying for the brand.

If your plan requires prior authorization for the authorized generic or an alternative inhaler, ask your doctor's office to submit a PA request. You can also ask about therapeutic equivalency to expedite the process.

What Should You Do Right Now?

Here's your action plan as of 2026:

1. Ask your pharmacist for the authorized generic (Fluticasone Propionate/Salmeterol MDPI by Teva) — same medication, often lower cost.
2. Contact your prescriber to update your prescription if it specifies the AirDuo brand.
3. Use medfinder to find a pharmacy that has the authorized generic in stock — faster than calling every pharmacy yourself.
4. Keep your rescue inhaler (albuterol) on hand and never skip your maintenance doses — if supply is delayed, call your doctor immediately.

The Bottom Line

The AirDuo RespiClick brand is gone, but the medication it contained is very much still available. The authorized generic from Teva is the easiest path forward for most patients. Use medfinder to check pharmacy stock in your area. And if you need to explore switching inhalers, see our guide to AirDuo alternatives for a full comparison.